• Travere Therapeutics presented Phase 3 PROTECT biomarker results for Filspari in IgA nephropathy at ASN Kidney Week 2026 in Denver.
• Filspari produced greater, sustained reductions in disease-related urinary biomarkers than irbesartan, suggesting it may modify underlying disease biology.
• The analysis included 295 of 404 trial participants, building on earlier findings of superior proteinuria reduction and slower kidney function decline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023530930) on October 23, 2026, and is solely responsible for the information contained therein.